Call to Action on Childhood TB

Notice from the Stop TB Partnership:

We are writing to encourage you to sign the Call to Action on Childhood TB.

The call was an outcome of an international meeting organized jointly by the European Centre for Disease Prevention and Control (ECDC) and the Stop TB Partnership’s Childhood TB Subgroup in March.

The meeting was attended by a wide range of participants, including researchers, paediatricians, community representatives, civil society organizations, and ECDC and WHO staff. The objectives of the meeting were to:

  • identify and highlight the gaps, challenges and needs in childhood TB control.
  • prepare the scientific rationale for the need for advocacy and to identify the key areas where more advocacy and targeted engagement with stakeholders are needed.
  • reach a consensus on how to advocate for childhood TB control.

There was strong consensus among participants on the urgent need to make the voice of children heard through concerted advocacy efforts. A detailed programme of the meeting, with all presentations, can be found at the ECDC website

The Call to Action is now available on the Stop TB Partnership website. Click here to sign.

Photo by John-Michael Maas

Learn more about childhood TB

Links to previous coverage of childhood TB by the WGND

WHO Releases Factsheet on Children and TB

MSF Podcast: Difficulties of Treating Children with TB

Interview with Dr. Anneke Hesseling: Part One, Part Two, and Part Three

TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children

Interview with Mark Cotton: Part One and Part Two

More News
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...
21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
12 Mar 2019
On March 8th, TB Alliance announced its novel compound, Pretomanid, is currently being reviewed by the FDA for use against Tuberculosis. TB Alliance's press release can be found below: NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug...